Murakami Yuichi 村上雄一

… Alternative Names

村上雄一ムラカミユウイチ

Less

Researcher Number	60464385
Other IDs	https://orcid.org/0009-0003-2971-8841
Affiliation (Current)	2025: 社会医療法人雪の聖母会(聖マリア研究センター), 基礎医学研究ユニット, 上級研究員
Affiliation (based on the past Project Information) *help	2024: 社会医療法人雪の聖母会(聖マリア研究センター), 基礎医学研究ユニット, 上級研究員 2016 – 2021: 九州大学, 薬学研究院, 共同研究員 2015: 九州大学, 薬学研究科(研究院), 研究員
Review Section/Research Field	Principal Investigator Basic Section 47060:Clinical pharmacy-related / Medical pharmacy
Keywords	Principal Investigator 薬剤耐性 / SRC / EGFR-TKI / オシメルチニブ / 細胞周期 / 卵巣癌 / YBX1 / Src family kinase / osimertinib / afatinib … More / ダサチニブ / 耐性 / 肺癌 / アファチニブ / EGFR / Gemcitabine / mTOR Less

Development of novel therapeutic approach for ovarian clear cell carcinoma targeting cell cycle regulation by A.Principal Investigator
- Principal Investigator
  
  村上雄一
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Our Lady of the Snow Social Medical Corporation (St. Mary
A novel therapeutic strategy targeting SFK for overcoming osimertinib resistance in lung cancerPrincipal Investigator
- Principal Investigator
  
  Murakami Yuichi
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Kyushu University
The activation of SFK contributes to the resistance to second and third generation EGFR-TKIsPrincipal Investigator
- Principal Investigator
  
  Murakami Yuichi
- Project Period (FY)
  2017 – 2018
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kyushu University
A mechanism how mTOR inhibitor potentiate the effect of gemcitabine against pancreatic cancerPrincipal Investigator
- Principal Investigator
  
  Murakami Yuichi
- Project Period (FY)
  2015 – 2016
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kyushu University

All 2020 2019 2018 2017 2016 2015

All Journal Article Presentation

[Journal Article] The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.2017
- Author(s)
  Murakami Y, Sonoda K, Abe H, Watari K, Kusakabe D, Azuma K, Kawahara A, Akiba J, Oneyama C, Pachter JA, Sakai K, Nishio K, Kuwano M, Ono M.
- Journal Title
  
  Oncotarget
  
  Volume: 8 Issue: 41 Pages: 70736-70751
- DOI
  10.18632/oncotarget.19982
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K15507, KAKENHI-PROJECT-17J03942
[Journal Article] Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression2017
- Author(s)
  Tomohiro Shibata, Kosuke Watari, Hiroto Izumi, Akihiko Kawahara, Satoshi Hattori, Chihiro Fukumitsu, Yuichi Murakami, Ryuji Takahashi, Uhi Toh, Ken-ichi Ito, Shigehiro Ohdo, Maki Tanaka, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono
- Journal Title
  
  Cancer Research
  
  Volume: 77 Issue: 2 Pages: 545-556
- DOI
  10.1158/0008-5472.can-16-1593
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15J03033, KAKENHI-PROJECT-15K18923
[Journal Article] Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.2016
- Author(s)
  Kuwano M, Sonoda K, Murakami Y, Watari K, Ono M.
- Journal Title
  
  Pharmacol Ther
  
  Volume: 161 Pages: 97-110
- DOI
  10.1016/j.pharmthera.2016.03.002
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K18923
[Journal Article] Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.2016
- Author(s)
  Watari K, Nishitani A, Shibata T, Noda M, Kawahara A, Akiba J, Murakami Y, Yano H, Kuwano M, Ono M.
- Journal Title
  
  Oncotarget
  
  Volume: 7 Issue: 30 Pages: 47403-47417
- DOI
  10.18632/oncotarget.10161
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K18923
[Presentation] オシメルチニブ耐性獲得の新しい分子機序：AXLとCDCP1の発現亢進はSFK活性化に緊密に関連する2020
- Author(s)
  村上雄一、日下部大樹、渡公佑、柴田智博、河原明彦、東公一、桑野信彦、小野眞弓
- Organizer
  第24回日本がん分子標的治療学会学術集会
- Data Source
  KAKENHI-PROJECT-19K07222
[Presentation] 肺癌のオシメルチニブ耐性にSFK,CDCP1,AXLの活性化が関与する2019
- Author(s)
  村上雄一、渡公佑、柴田智博、桑野信彦、小野眞弓
- Organizer
  第78回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K07222
[Presentation] 肺癌のオシメルチニブ耐性にSrcファミリーキナーゼの活性化が関与する2018
- Author(s)
  村上雄一、渡公佑、柴田智博、桑野信彦、小野眞弓
- Organizer
  第77回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-17K15507
[Presentation] ゲムシタビンとmTOR阻害剤の併用による相乗的な膵癌の増殖抑制効果のメカニズム2015
- Author(s)
  村上雄一, 渡公佑, 柴田智博, 河原明彦, 鹿毛政義, 桑野信彦, 小野眞弓
- Organizer
  第74回日本癌学会学術総会
- Place of Presentation
  名古屋国際会議場
- Year and Date
  2015-10-08
- Data Source
  KAKENHI-PROJECT-15K18923

1. 河原明彦 (00469347)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results

Murakami Yuichi 村上 雄一

村上 雄一 ムラカミ ユウイチ

Research Projects

Research Products

Co-Researchers

Development of novel therapeutic approach for ovarian clear cell carcinoma targeting cell cycle regulation by A.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

A novel therapeutic strategy targeting SFK for overcoming osimertinib resistance in lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

The activation of SFK contributes to the resistance to second and third generation EGFR-TKIsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

A mechanism how mTOR inhibitor potentiate the effect of gemcitabine against pancreatic cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.2017

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression2017

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.2016

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.2016

Author(s)

Journal Title

DOI

Data Source

[Presentation] オシメルチニブ耐性獲得の新しい分子機序：AXLとCDCP1の発現亢進はSFK活性化に緊密に関連する2020

Author(s)

Organizer

Data Source

[Presentation] 肺癌のオシメルチニブ耐性にSFK,CDCP1,AXLの活性化が関与する2019

Author(s)

Organizer

Data Source

[Presentation] 肺癌のオシメルチニブ耐性にSrcファミリーキナーゼの活性化が関与する2018

Author(s)

Organizer

Data Source

[Presentation] ゲムシタビンとmTOR阻害剤の併用による相乗的な膵癌の増殖抑制効果のメカニズム2015

Author(s)

Organizer

Place of Presentation

Year and Date

Data Source

Murakami Yuichi 村上雄一

村上雄一ムラカミユウイチ